An Open Label Phase IIb Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 35
Maximum Age: 75
Healthy Volunteers: f
View:

• Adults between the ages of 35 - 75 years Body Mass Index (BMI) less than 39 kg/m2

• Ambulatory and in good general health

• Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions

• Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Treatment

• Kellgren-Lawrence grading scale score of 3 or 4 for OA of the knee

• No clinically significant abnormalities observed in medical history, physical exam vital signs, and laboratory assessments

• For females of reproductive potential: use of effective contraception for at least 1 month prior to screening and agreement to use such a method till end of the study period and negative pregnancy test

• For males of reproductive potential: use of condoms and other methods to ensure effective contraception

Locations
United States
Nevada
Orthopedic & Sports Medicine Institute of Las Vegas
RECRUITING
Las Vegas
Contact Information
Primary
Vince Liguori
vince@agebiomed.com
847-561-0217
Backup
Mukesh Kumar, PhD RAC
mkumar@fdamap.com
2407504893
Time Frame
Start Date: 2025-05-21
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 400
Treatments
Experimental: OA-SYS
Treatment with OA-SYS
Related Therapeutic Areas
Sponsors
Leads: Ageless Biotech, Inc.

This content was sourced from clinicaltrials.gov